



Cara Therapeutics
Investor Relations Department
107 Elm St. 9th Flr
Stamford, CT 06902
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CARA

Last Trade:	12.10
Trade Time:	4:00 PM ET Nov 20, 2017
Change:	-0.08 ↓ (-0.657%)
Day Range	12.04 - 12.29
52-Week Range	8.61 - 28.50
Volume	630,662

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

We are developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. Our most advanced product candidate, intravenous, or I.V... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Nov 8, 2017
Cara Therapeutics to Present at November Investor Conferences](#)
- [Nov 2, 2017
Cara Therapeutics Reports Third Quarter 2017 Financial Results](#)
- [Oct 31, 2017
Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting](#)
- [Oct 26, 2017
Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017](#)
- [Oct 25, 2017
Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients](#)

Upcoming Events [\[View all \]](#)

- [Nov 28, 2017 11:00 AM ET
29th Annual Piper Jaffray Healthcare Conference](#)
- [Mar 10, 2017
Annual Report \(10-K\)](#)
- [May 10, 2017
Proxy Statement \(DEF 14A\)](#)
- [Nov 2, 2017
Quarterly Report \(10-Q\)](#)
- [Aug 3, 2017
Quarterly Report \(10-Q\)](#)
- [May 4, 2017
Quarterly Report \(10-Q\)](#)